Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 82INDUSTRY 66NIH 9NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 1

Interventions

Cytarabine 7Busulfan 7Cyclophosphamide 6Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5fludarabine 4Methotrexate 4fludarabine phosphate 3Tacrolimus 3Radiotherapy 3Melphalan 3Daunorubicin 3Cyclosporine 3Asparaginase 3merphos 2Thioguanine 2Patient Reported Outcome Measures 2Mitoxantrone 2Mesna 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Gemtuzumab 2Filgrastim 2Bone Marrow Transplantation 2Azacitidine 2Antilymphocyte Serum 2zosuquidar trihydrochloride 1treosulfan 1thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Myelodysplastic Syndromes × Azacitidine × Clear all
NCT01048034 2013-10-29

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Nordic MDS Group

Phase 2 Completed
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01556477 2012-03-16

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Nordic MDS Group

Phase 2 Unknown
72 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡